PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
The whole armory of the drugs used in rheumatology is employed to treat systemic lupus erythematosus (SLE); how- ever, most of them have not got regulatory authorities' approval and are used off-label for SLE. The successful use of a biological agent rituximab (anti-CD20 monoclonal antibodies)...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2014-06-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1946 |